The FDA just held a two-day Public Advisory Committee Meeting during which physicians, patients, and industry representatives convened to discuss breast implants. Breast implant illness (BII) and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) were amongst the topics. Due to